Preclinical pharmacokinetics and tolerability of a novel meglumine‐based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus.

MLA

Rundfeldt, Chris, et al. “Preclinical Pharmacokinetics and Tolerability of a Novel Meglumine‐based Parenteral Solution of Topiramate and Topiramate Combinations for Treatment of Status Epilepticus.” Epilepsia (Series 4), vol. 64, no. 4, Apr. 2023, pp. 888–99. EBSCOhost, https://doi.org/10.1111/epi.17520.

APA

Rundfeldt, C., Klein, P., Boison, D., Rotenberg, A., D’Ambrosio, R., Eastman, C., Purnell, B., Murugan, M., Goodkin, H. P., & Löscher, W. (2023). Preclinical pharmacokinetics and tolerability of a novel meglumine‐based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus. Epilepsia (Series 4), 64(4), 888–899. https://doi.org/10.1111/epi.17520

Chicago

Rundfeldt, Chris, Pavel Klein, Detlev Boison, Alexander Rotenberg, Raimondo D’Ambrosio, Cliff Eastman, Benton Purnell, Madhuvika Murugan, Howard P. Goodkin, and Wolfgang Löscher. 2023. “Preclinical Pharmacokinetics and Tolerability of a Novel Meglumine‐based Parenteral Solution of Topiramate and Topiramate Combinations for Treatment of Status Epilepticus.” Epilepsia (Series 4) 64 (4): 888–99. doi:10.1111/epi.17520.